stocktitan.net
Cure8 news brief
Why This Matters
This report describes open‑label extension data for ontunisertib, an investigational oral drug being tested specifically for fibrostenosing Crohn’s disease.
Results suggest low surgery rates and potential stricture stabilization, and a larger randomized Phase 2b is planned — which could matter to patients and clinicians tracking new therapies for stricturing disease.
Who Should Pay Attention
Patients with fibrostenosing Crohn’s disease, clinicians treating stricturing disease, researchers and trial participants interested in emerging anti‑fibrotic or gut‑targeted therapies, and stakeholders following Agomab/AGMB development.
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
Agomab reported results from the STENOVA open‑label extension of ontunisertib in fibrostenosing Crohn’s disease (49 patients rolled into a 48‑week extension, up to 60 weeks total).
The company described safety as generally favorable, five serious adverse events judged unrelated or unlikely related to treatment, low systemic drug exposure, imaging suggesting stricture stabilization, one endoscopic balloon dilation and no surgeries, and a 3% annualized disease‑related event rate.
Agomab says regulatory filings for the planned ~320‑patient NOV‑ERA Phase 2b are complete and the randomized trial is expected to start in the coming months. This appears to be a company press/market report summarizing the open‑label extension data rather than a peer‑reviewed paper.
Optional Week 48 endoscopy data were too limited for reliable interpretation per the report, and the extension is open‑label without a placebo control, so efficacy interpretation is limited. The upcoming NOV‑ERA Phase 2b will be randomized across three doses and placebo; that trial will be needed to assess efficacy more robustly.
If you are following drug development for fibrostenosing Crohn’s disease, this is an early positive signal but not definitive evidence of benefit. Discuss any implications for your care with your treating clinician; this report does not change approved treatment recommendations.
Keep In Mind
The source is a market/press report summarizing company data from an open‑label extension. Open‑label extensions lack placebo control and have selection biases; optional endoscopy data were limited, and the planned Phase 2b randomized trial will provide more rigorous evidence. The article is not a peer‑reviewed publication.
Source Details
Review the original publication for the complete reporting, methods, and context.
Phase 2 clinical trial
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationstocktitan.net
PublisherStock Titan
AuthorsAgomAb Therapeutics NV
Indexed viaGoogle News
Source typeWeb article
PublishedOct 1, 2026, 4:33 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...
Agomab stock jumps on positive trial data
The report suggests an investigational, gut-restricted ALK5 inhibitor (ontunisertib) had sustained symptom control, high remission rates, and few procedures or surgeries in an open-label extension for fibrostenosing...